Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabis Oil for Comorbid Symptoms in Children with ASD
NCT05212493Phase 3Completed
- Sponsor
- Shamir Medical Center
- Start
- Nov 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cannabis oil in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Shamir Medical Center. Primary endpoints: Cannabinoids levels change at 3 months, Changes in attention span at 6 months and 4 more. Started Nov 2019; status: completed.
02
Drugs
cannabis oil
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05212493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212493.